NEW YORK, NY / ACCESSWIRE / March 31, 2020 / EDAP TMS SA (NASDAQ:EDAP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 31, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60940

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 583272

NEW YORK, NY / ACCESSWIRE / March 31, 2020 / WIMI Hologram Cloud has already filed with SEC for IPO on NASDAQ global market.

With the development of 5G holographic communication, WIMI Hologram Cloud is building a leading Holographic Augmented Reality application platform in China.

Market Potential across the Holographic AR Value Chain

As holography and AR continue to proliferate, China's holographic AR market is fast-growing and evolving. According to Frost & Sullivan, the total market size of China's holographic AR industry in terms of total revenues is expected to grow from RMB 3.6 billion in 2017 to RMB 454.8 billion in 2025.

Cutting-edge Technology Capabilities and High-Quality User Experience

The company has developed the professional media player in China specifically designed for holographic AR contents. It has built in a comprehensive set of setting parameters and editing tools used for holographic AR content playback and allows end-users to playback complex high-fidelity simulations quickly and cost-effectively. End-users are able to adjust the contrast, saturation and vibrancy of the displayed holographic AR content and create their own custom visual effect.

Experienced Management Team

The company benefit significantly from the experience of WIMI's founder and senior management team, who have been successfully riding the growth wave in China's booming holographic AR industry. WIMI's chairman, Mr. Jie Zhao, has been with WIMI's company since WIMI's inception and possesses deep entrepreneurship and extensive expertise in the internet industry. Prior to establishing WIMI's company, Mr. Zhao founded Weixun Yitong, a mobile internet platform in China. Mr. Fanhua Meng, WIMI's Chief Executive Officer, has over ten years of senior management experience in internet companies. Mr. Shuo Shi, WIMI's Chief Operations Officer, is experienced in sales marketing, internet management and culture media. Mr. Yanghua Yang, the Chief Financial Officer of WIMI's company, has over ten years of experience in audit and finance. Mr. Chengwei Yi, WIMI's Chief Technology Officer, has over 15 years of experience focusing on video processing technology, artificial intelligence and signal processing technology. The company believes that WIMI's management team's collective experience and insights have paved and will continue to pave the way for WIMI's success. WIMI's management team is supported by a research and development team with strong academic background and industry expertise in audio/video processing, 3D modeling and cloud computing.

CONTACT:

Name: Tim Wong
Email: bjoverseasnews@gmail.com
Tele: +86 10 89913328

SOURCE: WiMi

ReleaseID: 583259

GUILDFORD, SURREY / ACCESSWIRE / March 31, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update in relation to the impact of the Coronavirus (COVID-19) pandemic on its business.

ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. We take the health, safety and wellbeing of our staff, blood donors and the broader community very seriously. Following the UK Prime Minister's announcement on 23 March 2020 that UK citizens should only leave their homes for certain very limited purposes, we took the decision to temporarily cease operations at the ANGLE UK laboratories and offices. Throughout the medical device and diagnostic industry, the COVID-19 pandemic is severely disrupting clinical trials and research studies due to the temporary cessation of patient enrolment along with associated research activities at clinical sites. These extraordinary measures have been taken in order to allocate resources to healthcare systems and to seek to reduce the spread of COVID-19.

As a response to the domestic and global COVID-19 situation, ANGLE has implemented its business continuity plan and can provide the following update on its ongoing clinical work.

US Food and Drug Administration (FDA) Submission

ANGLE has been following its stated plan and working flat out on the FDA De Novo Submission in metastatic breast cancer for the Parsortix® system. Although this work is very near completion, there are still a small number of analytical samples to be processed, which require healthy volunteer donor blood. The Prime Minister's announcement on 23 March resulted in the immediate loss of availability of healthy volunteer blood donors, which was a key factor in our decision to temporarily close our UK laboratory.

Since the announcement by the UK Government on 23 March, the ANGLE team has investigated how the remaining analytical samples could be completed given the exceptional circumstances and/or whether the submission can be made without these components. Taking into account the current government advice and ANGLE's commitment to the safety of its staff, blood donors and the broader community, ANGLE do not feel it would be advisable or ethical to move forward with the collection of blood samples at this time. In addition, the expert advice we have received recommended that a submission without the remaining analytical studies included would have a high probability of being viewed as incomplete by the FDA, and is consequently not feasible.

We are therefore completing the full write up of the submission with the aim that within a few weeks of the current government restrictions being relaxed we will be able to reinstate healthy volunteer blood collection, process the final analytical samples and make our FDA submission. Given the current circumstances, we cannot be sure of the likely timing for these blood collections, when we might make our submission or how long the FDA will take to review our submission. The outcome and timing of any subsequent FDA regulatory decision is also entirely dependent on the FDA's review and response to the Company's submission. ANGLE will update the market once the submission to the FDA has been made.

Ovarian Cancer

ANGLE's ovarian cancer clinical verification study (EMBER2) is in progress, with enrolment by the University of Rochester Medical Center (URMC) Wilmot Cancer Institute, New York, USA to evaluate the use of ANGLE's combined Parsortix® and HyCEAD™ Ziplex® platforms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass.

A positive outcome from the study will support ANGLE's plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass, with both high sensitivity (correctly detecting cancer) and high specificity (correctly detecting no cancer with a low false positive rate).

Unfortunately, as with all other major US cancer centres, URMC has temporarily ceased all elective surgeries, patient enrolment, and research laboratory activities to deploy resources towards the prevention and treatment of coronavirus. It is currently unknown when patient enrolment into the EMBER2 study will recommence. Consequently, the study will not now report mid-year. The timing of the US Government lifting restrictions and patient enrolment recommencing is outside of the Company's control. ANGLE will update the market once the ovarian cancer clinical verification study patient enrolment recommences.

Other matters

Research use sales are currently in the establishment phase and are modest, and therefore do not have a material impact on the Company's short-term cash position, especially in light of the reduced sales and marketing costs during this period.

ANGLE is working on a number of proactive business development programmes that aim to put the Company in the strongest possible position once government restrictions are lifted. These include continued proactive efforts to establish relationships and in-house procedures to drive forward the use of the Parsortix system in contract services for pharmaceutical companies ("Pharma Services") for cancer drug trials; and the development of partnerships with major corporate partners to the benefit of both organisations.

As previously reported, ANGLE has sufficient cash for planned operations until mid-2021. As at 30 March 2020 the Company had a cash balance of £15.5 million, an R&D tax credit due from HMRC of £1.9 million and a further R&D tax credit of c. £1.5 million to be submitted after completion of the audit. Plans are being reviewed and certain expenditures may be reduced and/or deferred to extend this runway further.

Following an announcement to change the Company's year-end, ANGLE previously announced that it would be releasing its preliminary results for the eight month period to 31 December 2019 in April 2020. Under the current circumstances, the Company now plans to release its preliminary results in May, with Accounts posted to shareholders in June and the Annual General Meeting (AGM) held at the end of June or in July, which is anticipated to be a virtual AGM. Given the continued uncertainty as a result of COVID-19, the Board does not believe it appropriate to provide guidance for future financial years at this time.

ANGLE Founder and Chief Executive, Andrew Newland, commented:
"At ANGLE we are committed to the health and well-being of our employees, our clinical study participants, and our healthy volunteer blood donors. We have taken the necessary steps to ensure the safety of all of these groups during the COVID-19 pandemic, which has led us to temporarily pause our FDA submission and ovarian cancer study. I am deeply disappointed for cancer patients and their families, our shareholders, customers, partners and staff that we are having to temporarily pause such important work, but we believe that we have no alternative.

We are fortunate to have a strong cash position and no debt so that we can work through this exceptionally challenging time.

Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018 with an estimated 18.1 million new cases every year and some 43.8 million living with and after cancer. The need for a simple blood test alternative to tissue biopsies is being even further demonstrated in the current situation as cancer surgeries for critically important metastatic tissue biopsies are being cancelled or postponed. ANGLE offers a unique proprietary solution to address this key medical need."

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance – Carl Holmes, Simon Hicks

ECM – Alice Lane, Sunila de Silva

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

+44 (0) 203 705 9330

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

+44 (0) 203 727 1000

+1 (212) 850 5624

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2015.

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide cells of interest to users in a format suitable for multiple types of downstream analyses. The system uses a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen, as being a complete cell allows DNA, RNA and protein analysis, and the live cells harvested can also be cultured. The Parsortix technology is the subject of 24 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide. The Parsortix system has a CE Mark in Europe for the indicated use and submission to FDA for clearance is in process for the United States using results from two separate clinical studies of over 250 metastatic breast cancer patients and associated analytical studies. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system and only the third ever FDA cleared liquid biopsy test. ANGLE has already undertaken two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (ROC-AUC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation, and is currently in the process of a 200 patient clinical verification study.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (ROC-AUC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 30 peer-reviewed publications and numerous publicly available posters, available on our website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

ReleaseID: 583211

MONTREAL, QC / ACCESSWIRE / March 31, 2020 / Amex Exploration Inc. ("Amex or the Company") (TSX-V:AMX, FRA:MX0, OTCQX:AMXEF) announces changes to its planned Annual and Special Meeting of Shareholders and is providing an update on its operations with respect to the COVID 19 pandemic. In complying with government guidelines, the Annual and Special Meeting of Shareholders scheduled to take place on April 7, 2020, has been moved to May 4, 2020 at 10:30 am (the "Meeting"). The Meeting will either take place at the offices of Amex located at 410 St Nicholas, suite 236, Montreal, Quebec in person or by virtual means, as will be appropriate at such time to ensure the health and safety of all participants. The record date of March 3, 2020, remains unchanged and all information contained in the meeting materials sent to shareholders on March 17, 2020 remains valid, except for the proxy cut-off date which will be extended to April 30, 2020 at 10:30 a.m. and the change of the meeting date to May 4, 2020.

In addition, pursuant to the mandated direction from the Government of Quebec regarding precautionary and preventative methods for COVID-19 pandemic, Amex is temporarily suspending, until April 13th or as mandated by the Government of Quebec, its fully funded drill program on the Perron Property. The temporary suspension of drilling coincides with the traditional spring break-up period at Perron. Amex' geologists and management are working from home offices and the Company is using this time for data compilation, modelling and drill planning. Amex is well positioned with relatively low overhead costs and $9.7M in cash and cash equivalents.

Dr. Jacques Trottier, Executive Chairman of Amex Exploration said, "Our priority is the health and safety of everyone at our site especially during this difficult time and we are strictly following the new Quebec Government regulations. We have had several very active months of successful drilling on all three gold zones at Perron. Given our proximity to infrastructure and access to dry competent ground, the drills will remain on-site in position and so restarting the drill campaign will be very quick."

About Amex

Amex Exploration Inc. is a junior mining exploration company, the primary objective of which is to acquire, explore, and develop viable gold and base metal projects in the mining-friendly jurisdictions of Quebec and Ontario. Amex is focused on its 100% owned Perron gold project located 110 kilometers north of Rouyn Noranda, Quebec, consisting of 116 contiguous claims covering 4,518 hectares. A number of significant gold discoveries have been made at Perron, including the Eastern Gold Zone, the Gratien Gold Zone, the Grey Cat Zone, and the Central Polymetallic Zone. High-grade gold has been identified in each of the zones. A significant portion of the project remains underexplored. In addition to the Perron project, the company holds a portfolio of three other properties focused on gold and base metals in the Abitibi region of Quebec and Ontario.

For further information please contact:

Victor Cantore
President and Chief Executive Officer
Amex Exploration: 514-866-8209

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements:

This news release contains forward-looking statements. All statements, other than of historical facts, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the planned exploration program on the HGZ and LGZ, the expected positive exploration results, the extension of the mineralized zones, the timing of the exploration results, the ability of the Company to continue with the exploration program, the availability of the required funds to continue with the exploration and the potential mineralization or potential mineral resources are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "to earn", "to have', "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, failure to meet expected, estimated or planned exploration expenditures, failure to establish estimated mineral resources, the possibility that future exploration results will not be consistent with the Company's expectations, general business and economic conditions, changes in world gold markets, sufficient labour and equipment being available, changes in laws and permitting requirements, unanticipated weather changes, title disputes and claims, environmental risks as well as those risks identified in the Company's annual Management's Discussion and Analysis. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described and accordingly, readers should not place undue reliance on forward-looking statements. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements except as otherwise required by applicable law.

SOURCE: Amex Exploration Inc.

ReleaseID: 583129

LONDON / ACCESSWIRE / March 31, 2020 / Midatech Pharma PLC (AIM: MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients announces that, in view of prevailing conditions in the capital markets and the prospects for raising additional funds and partnering of assets, the Board of Midatech is in the process of implementing a strategic review of its operations.

The Company believes the remaining costs to complete the Phase III clinical programme of MTD201 (octreotide sustained release) and manufacturing scale-up at its Bilbao facility are of the order of $30 million. Of this amount, $8.5 million has been raised in loans from the Spanish government. The Board has concluded, in the context of its current cash runway, that the Company is unlikely to conclude a license transaction or raise sufficient funds to continue the required remaining investment in MTD201 on a timely basis. The Board has therefore decided to terminate further inhouse development of the MTD201 programme with immediate effect. The Company will continue to seek licensing partners for this asset.

The Company announced on 5 December 2019 that it has been provisionally awarded a €2.6 million grant under the EU EIC Accelerator SME Instrument to part fund the GlioKIDS trial of MTX110 in DIPG, a terminal childhood brain cancer. Because of a technicality, the EU has not yet confirmed Midatech's status as an SME, a prerequisite for grant eligibility. The GlioKIDS Phase II trial of MTX110 may be cancelled if the EU grant is not received. The Company will continue the exploratory Phase I study of MTX110 with Columbia University announced on 2 March 2020.

In line with the decision to terminate MTD201, the Board has taken the difficult decision to close the Company's MTD201 dedicated manufacturing facilities in Bilbao and offer redundancy to all 42 employees. Under Spanish law, the Company will now enter into a period of consultation with its Bilbao based employees. In addition, a further five UK-based employees in clinical research and administrative roles are being offered redundancy.

Following these changes, Midatech's remaining 20 employees and operations will be concentrated in Cardiff. The Company's near term goal is to deploy its proprietary drug delivery technologies to formulate a compelling portfolio of novel first-in-class sustained release formulations of products with significant commercial potential for licensing to pharmaceutical company partners at proof of concept stage. The Company has no plans to undertake additional trials in humans unless a license partner or grant funding has been secured.

The Board continues to consider options for extracting value from the Company's technologies including partnering its existing and upcoming proof of concept formulations and/or partnering a technology.

On the basis of the cost-cutting measures described above, repayment of Spanish government loans, and release of loan deposits, the Company expects to have a cash runway until early 2021 assuming the GlioKIDS grant is received and the MTX110 Phase II trial proceeds.

Craig Cook is stepping down as CEO and resigning as a Director of the Company with immediate effect. He is succeeded by current CFO Stephen Stamp who will have the combined roles of CEO and CFO while the Company concludes its strategic review. In addition, in line with the Company's streamlined strategy and operations and narrower focus, Dr Huaizheng Peng and Mr Frédéric Duchesne have resigned as Directors with immediate effect.

Commenting, Rolf Stahel, Chairman said: "On behalf of the Board, I would like to place on record our sincere thanks to Dr Craig Cook for his leadership, work and tireless efforts over many years establishing our leading edge technologies and pipeline in the most difficult of circumstances, and wish him every success in the future. We are also fortunate that in Stephen Stamp we have an internal candidate who can take over responsibility as CEO, ensuring continuity and a controlled handover. These are unprecedented times and the decisions we are announcing today regarding MTD201, our Bilbao manufacturing facility, and staff are regrettable but also necessary to give Midatech time to find and deliver a solution for all stakeholders. Unfortunately, recent events have caused us to re-evaluate our strategy and priorities to ensure that we can fulfil the potential of our technologies and pipeline. I must also thank Dr Huaizheng Peng and Mr Frédéric Duchesne for their counsel and support, particularly over these past few months."

Dr Cook, outgoing Chief Executive Officer of Midatech Pharma, said: "I have been with Midatech Pharma for six years and have enjoyed my time at the company, working with ground breaking technology, a superb team, and a supportive and very capable Board of Directors. We have achieved a great deal together in creating assets as we seek to make a tangible difference for patients suffering from debilitating and lethal diseases. I leave the business with a very skilled and strong leader in Stephen Stamp with an excellent team to support him to deliver value for shareholders and patients alike. The imminent restructuring of the business is painful, and which we tried everything to avoid in these challenging circumstances. The Company would not have achieved what it has without its employee's dedication and hard work, and I wish those departing Midatech every success in the future."

Commenting, Stephen Stamp, incoming CEO and CFO said: "Everybody connected with the Company believes our three drug delivery technologies can offer significant improvements in the biodelivery and biodistribution of pharmaceuticals. We have demonstrated that in pre-clinical models and in human studies in both MTD201 and MTX110. Events outside our control have overtaken us and it is truly regrettable that many gifted and dedicated people have lost their jobs. For those of us that remain, our focus now is to extract maximum value for stakeholders from MTX110 and our platform technologies."

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Stephen Stamp, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Joseph Green/ Laine Yonker

Tel: (646) 653-7030/ 7035

jgreen@edisongroup.com/ lyonker@edisongroup.com

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

ReleaseID: 583207

ESTONIA / ACCESSWIRE / March 31, 2020 /  Goldario- Dispersion to the World's Advanced Economy Goldario is a cryptocurrency token that is backed by the precious metals, stones, jewellery manufacturing & retail industry, which is considered to be among the most valuable industries in the world of the traditional economy today.

Worth $279 billion in 2018, the worldwide estimation of the gems and jewellery market is expected to increase to approximately $480 billion by 2025. There are different processes that are involved in producing these gems and jewellery from their raw state when mined to their finished state where they can be used by consumers as jewellery.

It is pretty difficult and close to impossible for a small-scale investor to delve into this lucrative and high rewarding industry due to the expensive and cumbersome processes that are involved in creating these items. The business operation of Goldario does not only deal in Emerald Mines, as they own a Gemstones Cutting and Polishing Factory, a Jewellery Manufacturing Company, and jewelry retails business.

The project already has an established infrastructure in Brazil that is registered with company name G44 SA and possesses Emerald Mines that has an estimated deposit of $3 billion.

About The GLD Token

With the Goldario (GLD) token, big-time investors, as well as small scale investors with low ventures, can own a Gold and Emerald mining, Jewellery Manufacturing and Retail Shops business as the holders of this token are apportioned a digitized share in gold and emerald mines and in-house jewellery making for the world market that will help them to earn profit from various underlying businesses.

The token is a blockchain-based cryptocurrency that was built on the Ethereum blockchain (ERC-20). Every investor of the GLD token during the token sale is entitled to some portion of a potential and passive income creating business.

How GLD Can Revolutionize the Jewellery Industry

The priority of the Goldario platform is not only on the usage of the GLD token as it also encourages investors to maximize their chances of investing in the precious metals industry by affording them the opportunity to redeem their GLD tokens in the form Gems and Gold Jewellery through the launch of the GLD token.

GLD is in a great position to become the leading platform of choice for the consumers and various businesses that deal in the jewelry industry, as it offers a potential underlying asset backing which allows users to obtain and have entitlement over physical mines, jewelry production factories, and Jewellery retail businesses from across the world.

Key Facts About the GLD Token

The GLD token is considered to be a competitor to established cryptocurrencies like Bitcoin and is open to global business investors and cryptocurrency lovers. The following are reasons why the GLD token should be considered.

It is a first of its kind cryptocurrency to be used in the redemption of Gems and Gold.
Its owners are a world-renowned and registered group of company with existing successful businesses.
It has a lower investment plan that starts from $125 which small scale investors can take advantage of.
It has a cryptocurrency exchange that is called the Inoex Exchange.
It utilizes the trustless system of the blockchain.
It is expected to be a top-ranking cryptocurrency in a few years time.
It can be exchanged to fiat currencies such as the USD, EURO and Pounds very easily.

Why You Can Trust Goldario

Goldario is a project of a registered company with operating businesses like the Emerald and Gold Mines, the Jewellery Brand, the Cryptocurrency Exchange business locally operating in Brazil and the Jewellery Factory all fully and legally licensed, giving it a positive image to be adopted as a standardized currency all over the world.

The Future Looks Bright with The Goldario Blockchain Project

Goldario began their journey to success in 2018 when they created the InoexCryptocurrency Exchange, it was supposed to be the original plan and strategy behind the launch of the GLD token under an ICO platform that is backed by the precious stones, metals and the jewellery manufacturing network ecosystem. The launch of the GLD token is expected to position the Goldario blockchain project among the top blockchain projects due to its competitive nature and commitment to the world of the digital economy.

Requirements to be a Part of Goldario

What is expected from an investor to be a part of this digital economic system with multiple benefits is quite easy and convenient, they only have to buy a block processor during the ongoing token presale at the cost price of $1 USD per GLD token with a base start breaking point of $125 USD.

Crowd Sale Information

Start of Token Crowd sale: Date 01-07-2020
Duration: 180 days
Token symbol: GLD
Token standard: ERC-20 (For Token Sale)
Soft cap: 300 million USD
Hard cap: 1 Billion USD
Total token supply: 1,000,000,000
Token price: 1.00 USD per token
Bonus allocation: 30%

Goldario is a project that looks to change the cryptocurrency industry by providing a business with a worthy commercial value. Its community program is designed by experts using block processors and a reward program with a direct referral bonus, suitable for all investors, to ensure a quick sale of tokens.

Useful Links

Official Website: https://goldario.com
Facebook page: https://www.facebook.com/Goldario.token/
Twitter: https://twitter.com/GoldarioToken
Instagram: https://www.instagram.com/goldariotoken/
YouTube Channel: https://www.youtube.com/c/Goldario
Bounty Program: https://www.goldario.com/bounty/
Buy Tokens: https://office.goldario.com/register/

Contact:
Name: Goldario
Email: contact@goldario.com

SOURCE: Goldario

ReleaseID: 583243